Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Diabetes

Free Subscription Articles published in Am Heart J Retrieve available abstracts of 22 articles: HTML format

Single Articles

July 2025
1. MAKUVIRE TT, Latif Z, Atwater S, Shah MK, et al
   Health Care Access and Risk Factor Control in US adults with Cardiovascular Disease from 2015 to 2023.
   Am Heart J. 2025 Jul 2:S0002-8703(25)00208-X. doi: 10.1016/j.ahj.2025.
   PubMed     Abstract available
   
   
   May 2025
2. JAMES S, Christoffersen AD, David JP, Hacker M, et al
   Effect of Once-Weekly Subcutaneous Semaglutide on Arterial Inflammation in People with Type 2 Diabetes and Cardiovascular Disease Using PET-MRI: Primary Results of a Randomized, Double-Blind, Placebo-Controlled Trial.
   Am Heart J. 2025 May 7:S0002-8703(25)00156-5. doi: 10.1016/j.ahj.2025.
   PubMed     Abstract available
   
   
   April 2025
3. DILLINGER JG, Pezel T, Batias L, Angoulvant D, et al
   Twice-a-day administration of aspirin in patients with diabetes mellitus or aspirin resistance after acute coronary syndrome: Rationale and design of the randomized ANDAMAN trial.
   Am Heart J. 2025 Apr 21:S0002-8703(25)00132-2. doi: 10.1016/j.ahj.2025.
   PubMed     Abstract available
   
   
   March 2025
4. SERPA F, Perera S, Cruz D, Figueroa JF, et al
   Cardiovascular Health, Lifestyle Factors, and Social Determinants Among Hispanic or Latino Adults in the United States.
   Am Heart J. 2025 Mar 9:S0002-8703(25)00070-5. doi: 10.1016/j.ahj.2025.
   PubMed     Abstract available
   
   
   February 2025
5. CHATUR S, Seth M, Casey M, Thompson M, et al
   Reminders EMbedded IN PCI Reports to Optimize Discharge Diabetes Mellitus Care (REMIND-DM): Rationale, Design, and Baseline Characteristics.
   Am Heart J. 2025 Feb 21:S0002-8703(25)00019-5. doi: 10.1016/j.ahj.2025.
   PubMed     Abstract available
   
   
   
6. HAFF N, Horn DM, Bhatkhande G, Sung M, et al
   Encouraging the prescribing of SGLT2i and GLP-1RA medications to reduce cardiovascular and renal risk in patients with type 2 diabetes: rationale and design of a randomized controlled trial.
   Am Heart J. 2025 Feb 20:S0002-8703(25)00038-9. doi: 10.1016/j.ahj.2025.
   PubMed     Abstract available
   
   
   
7. TIAN Y, Wang X, Hu Z, Yu X, et al
   Design, rationale, and characterization of the Mobile health based OccuPational cardiovascular risk intErventioN study (mHealth-OPEN Study).
   Am Heart J. 2025 Feb 13:S0002-8703(25)00035-3. doi: 10.1016/j.ahj.2025.
   PubMed     Abstract available
   
   
   
8. GAO XF, Kan J, Wu HY, Chen J, et al
   Intravascular Imaging-guided versus Angiography-guided Percutaneous Coronary Intervention in Patients with Diabetes Mellitus: Rationale and design of an International, Multicenter, Randomized IVI-DIABETES Trial.
   Am Heart J. 2025 Feb 4:S0002-8703(25)00017-1. doi: 10.1016/j.ahj.2025.
   PubMed     Abstract available
   
   
   January 2025
9. EBRAHIMI M, Fonarow GC
   Higher Levels of Glucose within the Normal Range and Cardiovascular Risk: A Landscape Beyond Diabetes and Prediabetes.
   Am Heart J. 2025 Jan 23:S0002-8703(25)00008-0. doi: 10.1016/j.ahj.2025.
   PubMed    
   
   
   
10. BLOOD AJ, Chang LS, Colling C, Stern G, et al
    Type 2 Diabetes Disease and Management Patterns Across a Large, Diverse Healthcare System: Issues and Opportunities for Guideline-Directed Therapies.
    Am Heart J. 2025 Jan 6:S0002-8703(25)00003-1. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available
    
    
    December 2024
11. NELSON AJ, Kaltenbach LA, McGuire DK, Levya M, et al
    Discontinuation of SGLT-2i and GLP-1RA among persons with Type 2 diabetes and atherosclerotic cardiovascular disease treated in US cardiology clinics.
    Am Heart J. 2024 Dec 21:S0002-8703(24)00336-3. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available
    
    
    
12. HASSAN S, Chang LS, Gabovitch D, Chasse J, et al
    Enrollment strategies in the era of digital revolution: Experience from a remote health management program.
    Am Heart J. 2024;278:181-185.
    PubMed     Abstract available
    
    
    November 2024
13. NAVAS-ACIEN A, Mark DB, Anstrom K, Lamas GA, et al
    Response to Tomoyuki Kawada: Blood and urine metal levels in patients with diabetes and cardiovascular disease.
    Am Heart J. 2024;277:143-144.
    PubMed    
    
    
    
14. KAWADA T
    Blood and urine metal levels in patients with diabetes and cardiovascular disease.
    Am Heart J. 2024;277:142.
    PubMed    
    
    
    September 2024
15. KERCHEVAL JB, Narcisse DI, Nguyen M, Rao SV, et al
    Characterization of peripheral artery disease and associations with traditional risk factors, mobility, and biomarkers in the project baseline health study.
    Am Heart J. 2024;275:183-190.
    PubMed     Abstract available
    
    
    August 2024
16. HAMID H, Bagheri M, Benzing T, Krishnan S, et al
    Effect of tirzepatide on the progression of coronary atherosclerosis using MDCT: Rationale and design of the Tirzepatide treatment on coronary atherosclerosis progression: The (T-PLAQUE) randomized-controlled trial design: tirzepatide and plaque.
    Am Heart J. 2024 Aug 24:S0002-8703(24)00218-7. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available
    
    
    May 2024
17. COMMODORE-MENSAH Y, Chen Y, Ogungbe O, Liu X, et al
    Design and Rationale of the Cardiometabolic Health Program Linked with Community Health Workers and Mobile Health Telemonitoring to Reduce Health DisparitieS (LINKED-HEARTS) Program.
    Am Heart J. 2024 May 15:S0002-8703(24)00123-6. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available
    
    
    
18. JANUZZI JL JR, Liu Y, Sattar N, Yavin Y, et al
    Vascular endothelial growth factors and risk of cardio-renal events: Results from the CREDENCE trial.
    Am Heart J. 2024;271:38-47.
    PubMed     Abstract available
    
    
    April 2024
19. GAGNON LR, Hazra D, Perera K, Wang K, et al
    Uptake of SGLT2i and Outcomes in Patients with Diabetes and Heart Failure: A Population-Based Cohort and a Specialized Clinic Cohort.
    Am Heart J. 2024 Apr 24:S0002-8703(24)00094-2. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available
    
    
    
20. HEERSPINK HJ, Provenzano M, Vart P, Jongs N, et al
    Dapagliflozin and Blood Pressure in Patients with Chronic Kidney Disease and Albuminuria.
    Am Heart J. 2024;270:125-135.
    PubMed     Abstract available
    
    
    February 2024
21. RAO VN, Sharma A, Stebbins A, Buse JB, et al
    Regional variation in cause of death in patients with type 2 diabetes: insights from EXSCEL: Cause of Death in Type 2 Diabetes.
    Am Heart J. 2024 Feb 21:S0002-8703(24)00040-1. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available
    
    
    
22. ANDERSEN CF, Larsen JH, Jensen J, Omar M, et al
    Empagliflozin to elderly and obese patients with increased risk of developing heart failure: Study protocol for the Empire Prevent trial program.
    Am Heart J. 2024 Feb 14:S0002-8703(24)00032-2. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Diabetes is free of charge.